PARP Inhibitors for Prostate Cancer: 5 Things to Know Kate O'Rourke (+++ +++)

https://www.medscape.com/viewarticle/parp-inhibitors-prostate-cancer-5-things-know-2026a1000ocr?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312 Prostate cancer is the second most common cancer in men worldwide, with nearly 1.4 million new cases diagnosed each year. PARP inhibitors have transformed the treatment landscape for biomarker‑selected metastatic disease, moving from experimental agents to a core option for a subset of men with advanced prostate cancer. By exploiting defects in DNA repair — particularly homologous recombination repair (HRR) alterations such as BRCA1 and BRCA2 — these drugs can deliver meaningful survival gains after progression on standard hormone‑directed therapies. But their use is not one size fits all: benefit depends on tumor genomics, indications remain restricted to metastatic settings, and class‑specific toxicities such as anemia demand close monitoring and dose adjustment. ArteraAI: Current Indications in Prostate Cancer Suchandrima Bhowmik, MSc https://www.medscape.com/viewarticle/arteraai-current-indications-prostate-cancer-2026a1000sow?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312 ArteraAI is a multimodal AI (MMAI) platform that integrates digitized hematoxylin and eosin (H&E) histopathology slide images with patient clinical variables, such as age, tumor stage, prostate-specific antigen and Gleason score, to predict personalized patient outcomes and treatment response across different types of prostate cancer. ArteraAI is a multimodal AI (MMAI) platform that integrates digitized hematoxylin and eosin (H&E) histopathology slide images with patient clinical variables, such as age, tumor stage, prostate-specific antigen and Gleason score, to predict personalized patient outcomes and treatment response across different types of prostate cancer. https://www.pluvicto-hcp.com/?utm_source=onlinearticle&utm_mlr=FA-11663924&utm_medium=display&utm_campaign=onlinearticle_branded_pr~plvb_ch~de_bu~on_yr~26_cu~hcp_id~b0004oc6_ca~b_ind~plupsm_cn~2026-pluvicto-hcp-de_jan-2026&utm_content=plu_prostate-cancer_awareness_biolumina_ms_mb~plui_ca~ub_cm~pluvictohcpunbrandedstaticbannerad6-26_sp~standard_cd~fa-11663924_ed~2027-01-31_id~cta_cr~gbs_ct~track_sz~300x250&utm_placement=id~d002vsow_pr~plvb_fm~beml_pd~coeenewsletter_ad~sstrac_dt~cross_vv~vp0dv_pb~medscape_sp~medscadg_da~na_btg~std_ind~plupsm_cu~hcp_ca~b_sz~1x1-mb~plui_ca~ub_cm~pluvictohcpunbrandedstaticbannerad6-26_sp~standard_cd~fa-11663924_ed~2027-01-31_id~cta_cr~gbs_ct~track_sz~300x250&utm_mdm=%25%25MDM_ID%25%25&dclid=CjgKEAjwtp7VBhCf153ftoqcl00SJABlQDcez4M4O8NtcYEH8oEFrUFGvIYznFWwFg8E0nHUuAUeZ_D_BwE&gad_source=7&gad_campaignid=23709534173 Choosing Wisely in Prostate Cancer: Tailoring Treatment for Men With Limited Longevity Timothy J. Daskivich, MD, MSHPM; John T. Leppert, MD, MS https://www.medscape.com/viewarticle/choosing-wisely-prostate-cancer-tailoring-treatment-men-2026a1000jp2?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312 Active Surveillance Rises as Focal Therapy Persists in Prostate Cancer Frederik Joelving https://www.medscape.com/viewarticle/active-surveillance-rises-focal-therapy-persists-prostate-2026a1000srp?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312 Do High-Risk Features of Prostate Cancer Boost Hormone Therapy Benefit? Edited by Katie Lennon https://www.medscape.com/viewarticle/do-high-risk-features-prostate-cancer-boost-hormone-therapy-2026a1000rop?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312